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Abstract
Background: Hepatitis C (HCV) diagnosis and care is a major challenge for people who use illicit drugs, and is
characterised by low rates of testing and treatment engagement globally. New approaches to fostering
engagement are needed. We explored the acceptability of remote forms of HCV testing including self-testing and
self-sampling among people who use drugs in London, UK.
Methods: A qualitative rapid assessment was undertaken with people who use drugs and stakeholders in London, UK.
Focus groups were held with men who have sex with men engaged in drug use, people who currently inject drugs and
people who formerly injected drugs (22 participants across the 3 focus groups). Stakeholders participated in semi-structured
interviews (n = 5). We used a thematic analysis to report significant themes in participants’ responses.
Results: We report an overarching theme of ‘tension’ in how participants responded to the acceptability of remote testing.
This tension is evident across four separate sub-themes we explore. First, choice and control, with some valuing the
autonomy and privacy remote testing could support. Second, the ease of use of self testing linked to its immediate result
and saliva sample was preferred over the delayed result from a self administered blood sample tested in a laboratory. Third,
many respondents described the need to embed remote testing within a supportive care pathway. Fourth, were concerns
over managing a positive result, and its different meanings, in isolation.
Conclusions: The concept of remote HCV testing is acceptable to some people who use drugs in London, although
tensions with lived experience of drug use and health system access limit its relevance. Future development of remote
testing must respond to concerns raised in order for acceptable implementation to take place.
Keywords: Hepatitis C, HCV, Remote testing, Self testing, People who use drugs, Rapid assessment, Qualitative
Background
Hepatitis C (HCV) is a growing challenge globally. An
estimated 71 million people are living with chronic in-
fection, although only 1 in 5 people have been diagnosed
[1]. In England an estimated 160,000 people live with
chronic HCV infection [2]. People who inject drugs are
the group most affected by HCV in the UK, with up to
90% of chronic infections linked to injecting drug use
[3]. There is also a growing consensus that certain
groups of men who have sex with men are at high risk
of HCV infection linked to injection drug use and use of
certain psychoactive substances while having sex (‘chemsex’)
[4–7]. Recent surveys indicate that approximately half of
people injecting drugs in the UK are aware of their HCV
antibody positive status [2]. Low testing access has long
been linked to treatment challenges: historically (figures for
2012) only 3% of those living with HCV accessed then
available interferon-based treatment annually [8]. Treatment
options for HCV have however dramatically improved
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through the introduction of direct acting antivirals, poten-
tially enabling elimination of HCV as a public health threat
by 2030 [9–14]. In order for this to occur radical efforts are
needed to enhance diagnosis of HCV, particularly among
people who inject drugs [14].
In the UK, as globally, HCV testing uptake is low and
HCV treatment is difficult to access for people who use
drugs [1, 8, 15–23]. Global and UK guidance on HCV testing
emphasizes two stages: 1) an antibody test to establish HCV
exposure, generally using either rapid diagnostic tests of
blood or oral fluids, or laboratory based immunoassays; and
2) a polymerase chain reaction (PCR) test to confirm vir-
aemic (current ongoing) infection [24, 25]. In the UK both
tests are available from primary and secondary care, sexual
health and genitourinary medicine clinics as well as prisons,
drug treatment services and immigration centres [26, 27]. A
range of individual, organizational, social and structural fac-
tors complicate access to current testing modalities in the
UK, as globally: limited availability of testing; gaps in HCV
knowledge; mistrust in health services and providers (linked
to provider attitudes and stigma); provider reluctance to treat
HCV in the context of continued drug use; and provision of
services in tertiary centres which are less amenable to the
needs of people who use drugs [15, 21, 28].
A potential innovation to enhance testing access is re-
mote (or self, or home) testing [29]: testing outside clinic
settings and with the person themselves implementing
the test. Such an approach follows recent developments
in the promotion of remote self testing for HIV [30]. Re-
search literature on remote HIV self-testing indicates
benefits in terms of convenience, privacy and managing
stigma, but also highlights concerns around feasibility,
acceptability and potential for harm [31]. Within the
context of efforts to achieve HCV elimination, interest
in remote HCV testing is emerging [29].
We distinguish two forms of remote testing for HCV:
self-sampling (HCVSS) where an individual provides a
sample for testing that is sent to a laboratory, which is-
sues a result; and self-testing (HCVST) where an indi-
vidual operates a simple rapid test themselves and
interprets the result. In the UK remote HCV testing is
currently not regulated, supported by the National
Health Service nor included in associated guidelines and
procedures. Self-sampling for HCV is currently available
for private purchase through a number of regulated on-
line providers. Rapid diagnostic tests intended for clin-
ical use are also sold online and these can be used for
self-testing; these tests are unregulated in the UK and
are not designed for personal use, despite being mar-
keted as self-tests. Some countries have regulated use of
remote tests (e.g. USA [32]) but technologies and their
uptake are nascent.
To our knowledge there has been no published inves-
tigation in the UK or globally of the acceptability of
remote HCV testing for people who use drugs. Whilst
experiences of remote HIV testing are informative, HCV
may require different remote testing strategies to adapt
to specific aspects of the testing process [29], HCV
disease experience, prevailing social norms and care sys-
tems. Exploring remote HCV testing is essential to in-
form this potential policy priority. In response we aimed
to explore the acceptability of HCV remote testing
among people who use drugs in London, UK.
Methods
We used a qualitative rapid assessment methodology
that emphasises speed of research and linking assess-
ment to action. This approach reflects a pragmatic ap-
proach to public health research with an orientation to
intervention development and gaining findings adequate
for policy decision making [33, 34]. Specific methods
used were focus groups with people who use drugs and
semi-structured interviews with key stakeholders. Data
were generated in London, which has the largest propor-
tion of people who inject drugs living with HCV in the
UK [2], from January to March 2017.
For illustrative purposes only we obtained examples of
HCV self sampling and HCV self testing options. The
tests were not endorsed by the research team, the com-
panies who provided them had no input on study design,
data collection or analysis. The HCV self tests were in-
active prototypes of an oral fluid test, similar to rapid
diagnostic tests already available. The HCV self sampling
kits required a blood sample to be expressed in to a vial
and sent for laboratory testing.
Three focus groups were held. We sought to include
people over the age of 18 with current or past experi-
ence of injecting drug use or chemsex; exclusion criteria
were being younger than 18 years of age and having not
previously injected drugs or engaged in chemsex. Each
targeted a different drug-using population with the aim
of exploring potential variation in need for HCV testing,
in terms of current access to testing and how testing
could be delivered including how to support this with
appropriate messaging and information. Separate groups
were also organised to increase comfort and reduce the
impact of any stigma associated with particular iden-
tities, in that people may feel uncomfortable sharing
views about HCV with people with a distinct experience
to them. Groups comprised: 1. men who have sex with
men engaged in chemsex; 2. people who currently inject
drugs in contact with drug treatment; 3. people who
formerly injected drugs. Focus group participants were
recruited through partner community organisations, net-
works of the research team, social networking hook-up
apps aimed at men who have sex with men, social media
accounts of relevant support organisations and snowball
sampling. Key stakeholders were interviewed in order to
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provide insight to current delivery of HCV testing and
the policy environment for any testing innovation, as
well as to triangulate with the focus group data. Key
stakeholders were recruited through existing networks
of the London School of Hygiene and Tropical Medicine
and study partners. Focus groups and interviews were
informed by similar topic guides, both structured by
pre-identified domains of interest from the existing
literature [15, 17–19] and through discussions with
research partners. In both focus groups and interviews
we initially explored views and experiences in an open
and unstructured way, and then addressed specific ques-
tions on how issues such as stigma, health system logis-
tics and psychosocial support may be important for
respondents. Sample test kits were presented to inform
participants of the existing technologies and to facilitate
discussion; participants did not try the tests, but instead
had the chance to review and inspect them. Five stake-
holders (Table 1) were interviewed and 22 people partic-
ipated in 3 focus groups (Table 2). Focus groups each
lasted approximately 1.5 h, whilst stakeholder interviews
averaged half an hour.
We used a thematic analysis approach [35]. First level
coding used an a priori framework based on the inter-
view guide, such as perceptions of care access and
responses to a positive test results, to initially organise
the data. Second level coding within this organisation of
the data was inductive, focusing on prominent or signifi-
cant aspects of respondents’ accounts and oriented to
developing a grounded account of how participants
spoke about HCV testing [35]. Through the analysis we
compared data from the different focus groups and
interviews in order to understand if and how specific
experiences of views on HCV testing varied according to
the themes identified.
The research presented was undertaken with the
National Institute for Health Research Health Protection
Research Unit (NIHR HPRU) in Blood Borne and
Sexually Transmitted Infections at University College
London. The study obtained ethical approval from the
London School of Hygiene and Tropical Medicine (ref
12,054). All participants gave informed written consent.
Each participant in the focus groups received 40 GBP to
cover traveling expenses and time.
Results
We developed an overarching theme of ‘tension’ during
the analysis to explore the acceptability of remote testing
for people who use drugs. Our use of ‘tension’ as an
organising theme allowing expression of how responses
to the tests were sometimes contradictory and ambiva-
lent, or brought out issues that were described as not
easily resolved. We identify tension in how enthusiasm
for the principle of remote testing was reported along-
side flaws in the promise of remote testing, and also in
how its principle was seen as challenging to implement.
For example, individuals might express excitement for
remote HCV testing but also recognise inherent
challenges for people who use drugs:
I can certainly see the benefit in sitting at home in
private and doing it, I reckon a lot of people would be
in to that for all sorts of reasons. But it’s… I don't
know, it’s possible that maybe those same people are
the people that would be most worried if they got a
positive result. (S4)
Or accepting the principle of the tests, but alongside
concern at health system capacity to sustain them:
Pushing for testing is great, but I think that the fact
that even with the new drugs and the rationing…
you’ve still only got about 7% of those infected
accessing treatment each year … you push testing and
the chances are they won’t get treatment for years. I
think you really have to weigh that up carefully. (FG3)
The over-arching theme of tension reflects long standing
concerns around implementation of novel interventions
[36] and accounts for the sometimes competing priorities
and pressures that link the separate themes we report:
choice and control, ease of use, embedding testing in ap-
propriate care pathways, and managing an uncertain result.
In exploring each theme we draw attention to these ten-
sions and explore the implications of this in the discussion.
Choice and control
Many participants considered the potential choice and
autonomy over testing that a remote option might bring
as important:
I quite like the idea actually that you can do this
without the big faff around with your clinic, without
them taking control of it all, that you take control of it
and you take it home (S4)
The importance of autonomy was particularly evident in
response to a desire for privacy and to address stigma;
Table 1 Stakeholders interviewed
S1 S2 S3 S4 S5
Service manager from men who have sex with
men and use drugs outreach organisation
Drug user network
representative, living with HCV
Outreach worker,
living with HCV
Activist and campaigner,
living with HIV and HCV
HCV policy manager,
international organisation
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reported in the lives of participants both in relation to
drug use and HCV. Remote testing provided a way to
manage this stigma, through removing the need to
disclose to health care providers:
We can talk about de-stigmatisation and things, these
things take time and they take resources, etc. etc. and
in the meantime something like this can easily bridge
that gap I think (S1)
A sense of remote testing as an important choice and
focus for control was not universal, with some partici-
pants cautioning on the potential for particularly vulner-
able people to enact this ‘choice’ and whether it was
needed (as we discuss below), and also some questioning
whether this was a meaningful choice:
I don’t see the point… because once you do the test,
and you find out…so you have to run to the doctor. So,
why don’t you go in the first place? (FG2)
Ease of use
Tensions become particularly evident when participants
explored the practicality of implementing a test them-
selves. The different types of tests generated distinct re-
sponses on their ease of use. The self-sampling kit
required a blood sample by pricking a finger and then
squeezing blood in to a vial approximately half a centi-
metre wide. This was perceived by some as arduous,
complicated and painful to collect the required sample.
I would feel, God, there’s so many ways this could go
wrong. And also, even though there’s lots of
instructions, I think it’s the crucial moment, that point
of getting the… spiking your finger and getting the
blood out (FG1)
Such complications led to suggestions that the test
would be impractical for those experiencing extreme
hardship:
This wouldn't work at all. There's just too much
going on here on the second one [self sample] for
somebody who's homeless. Just wouldn't work at
all. (S2)
Although the ‘awkward’ nature of the self-test was offset
for some who felt more ‘confidence’ in the result it
would give.
The self-testing option – in essence a rapid diagnostic
test – was in comparison seen as beneficial in regard to
the immediacy of the result, simplicity of operation and
use of saliva rather than blood. It was felt to cater to a
wide range of abilities, something important for a target
population characterised by marginalisation.
I think it’s the accessibility of the test is what I enjoyed.
The first one, and knowing that I would get my result
immediately. Almost immediately. (FG2)
I suppose I think being saliva would probably be more
comfortable because I know myself, I get really
cautious around blood. (S3)
Embedding remote testing in appropriate care pathways
There were widespread concerns about ensuring appro-
priate care pathways, linked to fears people may be lost
to care. Many participants stated that remote testing
should be linked to education, support and follow-up
care: ‘the care pathway is so key to this and it has to be
clear’ (S1). A recurring response was for the need for
test access to be linked to engagement with a provider
or other expert who could give information and provide
support:
I don’t think it’s a solitary process this. I think you
need that support and that safety net in place,
whether it be for a peer or… I think what it’s got is
portability so you can go into a hostel with it and do
the test on that day. (S3)
Other responses suggested test access should be sup-
ported, whether through homeless hostels or specific
outreach processes – in effect meaning that remote test-
ing technologies would be delivered as community based
testing – or be offered within clinic settings linked to
clear information and support:
I think the priority would be hostels… I think it's
the best place to pick up the guys that are most at
risk. (S2)
Table 2 Participants in focus groups
FG 1 FG 2 FG 3
Men who have sex with men who use
drugs in ‘chemsex’ contexts
People who inject drugs in contact with drug services People who formerly injected drugs
8 participants: all men; average age 37
(range 26–52)
6 participants: 4 men, 2 women; average age 51
(range 48–55) – 3 did not report age
8 participants: 6 men, 1 woman, 1 trans female;
average age 49 (range 26–63)
3 previously had positive HCV result 3 previously had positive HCV result 3 previously had positive HCV result
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You initially have a discussion with the Consultant in
the clinic and they explain everything, and then you
can get them on order to your house every three
months, or whatever, with the understanding that if
you do get a positive result, or if you want to go back
in, you can go and discuss it with them. (FG1)
Online ordering was one suggested medium for remote
testing access. This was perceived as convenient, espe-
cially amongst those in the men who have sex with men
focus group, and to create a threshold to ensure people
had sufficient understanding, in response to the delinea-
tion of sufficient agency:
I also don’t want to disempower half the population
who are quite capable…I suppose if you are actively,
you have the abilities to go online and do that
research, maybe that’s the factor where you show that
you’ve got awareness and you’re sure about your
accountability. (S3)
However, as illustrated by this stakeholder who was
also a representative of a drug user network, an online
approach could exclude some, particularly among those
who had limited access to or interest in online services:
The only real drug users that are online are more the
psychoactive or psychoactives. Opiate users, crack users
aren’t online. No. Completely excluded. (S2)
Care pathway concerns were not universal. A self sam-
pling option was seen by some to be beneficial in that it
offered some basic linkage to specialist support, in terms
of a phone call to provide the result:
I’m sending it to a lab to be tested and I’m able to sit
at home and do it all in the privacy of my own home
and then send it away and then someone is going to
ring me up afterwards and say, hopefully, be a bit
thoughtful in how they tell me positive or negative. I
think that’s why I would prefer this one. (S4)
Remote testing for some men who have sex with men
was perceived to be of less overall utility in the context
of many in this group already having strong health sys-
tem access. There were reports of attending sexual
health clinics frequently for routine HIV and STI testing,
with the assumption that testing for HCV was embed-
ded within their sexual health care pathways.
Under what circumstances would I select Hep C for a
home test, if I’ve still got to go to the clinic for all my
other tests? You know, and is there some specific
reason for me to do it? … why bother to go through all
this risk and get, you know, all the anxiety I know I
would have with a positive reaction, when I’ve got to
go to the clinic in three months anyway for all my
other tests. (FG1)
Concerns extended to whether the health system could
provide a suitable care pathway. Sometimes grounded in
peoples’ own experiences of seeking HCV treatment,
there were complaints about the available infrastructure
that led to questioning the ethics of remote testing
under such conditions of scarcity:
Part of me wants to actually say “What?” I’m on a
waiting list waiting for [HCV] treatment. You get
awareness. Is the infrastructure in place for dealing
with an increase in people? (S3)
An unsupported and uncertain diagnosis
Participants raised concerns about how a positive test
result might be understood and experienced, particularly
if done in isolation. This was a barrier to the acceptabil-
ity of remote testing and undermined its potential as a
viable choice for many. Many participants suggested a
positive HCV result could cause ‘stress’, a ‘bad reaction’,
‘anxiety’ (FG1), ‘panic’ (FG2), be ‘serious relapse material’,
‘traumatic’ (FG 3), especially in the context of having no
direct link to care or support:
If you get a positive result and you’ve got no
information, that could be really scary…panic, panic,
panic. (FG3)
Accounts differentiated between groups and individuals
in the potential for managing a test result, distinguishing
between those with the knowledge or social support to
manage the choice remote testing offered, and those
who may struggle: those experiencing shame, with men-
tal illness or under the influence of drugs:
Maybe it should be for people who actually know what
they’re dealing with, who know what that is, and they
want just to test themselves. (FG1)
I don’t think it’s a great tool for somebody who’s at the
front line, cold face, bang on addiction. I think that it
has to be higher-up or further along the path. (S3)
Potential for alarm was compounded by confusion about
the meaning of a positive result. There was a wide-
spread, though not universal, lack of understanding of
HCV testing requiring two stages, of initial serological
tests to assess exposure, and then a confirmatory PCR
test to assess presence of the virus. The self test option
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for example shows exposure to the virus by testing for
antibodies, but not if the virus is currently active or has
been naturally cleared (which requires a PCR test). In re-
sponse, remote testing was seen as potentially ‘mislead-
ing’ (FG 1) with others highlighting the challenge of
understanding the testing process:
I’ve been in some discussions with some people.
There’ve been arguments between drug users when
someone said they’re Hep C but they don’t have it, and
somebody trying to get their head around that. If you
haven’t got the information to back it up, when you
explain that to someone it’s really hard to digest. (S3)
Confusion about the potential meaning of a test result
can be linked to the limited information in the test
packs. Neither test option explained the test result
meaning with reference to HCV antibodies or the virus
itself. However, one of the tests was a prototype, and so
accompanying information hadn’t been tailored for re-
mote use. Participants made requests for clarifying infor-
mation to be included with the tests to address the
uncertainty of a diagnosis and also on follow-up care:
We should have at least an information on this, you
would need some help straight away. If you get a
positive result and you’ve got no information, that
could be really scary (FG3)
Discussion
Using a rapid assessment approach, we qualitatively ex-
plored the acceptability of remote HCV testing for
people who use drugs in London. Our results show that
remote HCV testing generates responses characterised
by tension between competing pressures. There is
tension in how participants valued the potential for
choice from remote testing, whilst the enactment of
such principles is considered not feasible for some given
experiences of drug dependency, material hardship and
unsupportive health systems. Further tension comes in
how a principle benefit of remote testing is to potentially
separate testing from stigmatising and remote care
systems, and yet any positive result nonetheless requires
a supportive care system.
These tensions we understand as reflecting in part the
specific complexities of diagnosing and treating HCV
but also the social contexts and experiences for many
people who use drugs: experiences of economic and so-
cial marginalisation, as well as mistrust of care systems
grounded in stigma and abuse [21]. Given these ten-
sions, and concerns about receiving a test result in isola-
tion or that novel strategies are potentially less needed
for men who have sex with men using drugs reflecting
potentially strong health system access, the current re-
mote testing technologies may only be of utility and
value for some people who use drugs within the current
social and health system contexts. This could include
those not in contact with drug services (where HCV
testing should be widely available) but with an under-
standing of the HCV testing pathway and ability to
access and negotiate confirmatory testing and follow-on
care. This demographic may comprise people who
formerly injected drugs, medically literate but reticent to
disclose past risk practices in order to access a HCV test.
Considering this potentially limited relevance of remote
testing we recommend that remote testing be modified
and supportive health and social support systems
developed to enable broader acceptability and encourage
effective use.
In order to ensure broader acceptability we recom-
mend that developers of remote HCV testing technolo-
gies consult with local groups of people who use drugs
and service providers to ensure accompanying informa-
tion provided is relevant and accessible. Clarity is
required around what the test is testing for and – if for
antibody only – why a confirmatory test is required and
how to access it. A central concern among participants
was the potential for harm if a self-testing test result was
obtained in isolation (we note how the same concerns
have long been raised with HIV self testing, although
with little evidence of such harms [31]). This was com-
pounded by confusion between the meaning of test re-
sults [37, 38] and barriers to accessing confirmatory and
follow-on care. There is therefore a need for remote test-
ing to be developed and employed in tandem with com-
prehensive supportive care pathways [39, 40], and for
this detail to be included in accompanying information
with tests.
Participants indicated a desire for remote testing to be
integrated into clinic level care, or outreach and hostel
support as part of a supported care pathway, rather than
offered in isolation [41]. As suggested, outreach workers
could provide support and information, and then dis-
tribute tests and collect samples for testing, or be
available in the event of a positive test result in order
to aid interpretation and understanding (whether in
person, or over the phone). Such a pathway could
also enable referrals in to appropriate care. Explor-
ation and development of these pathways would miti-
gate some of the potential for harms noted, regarding
remote testing confusion, lack of support and associ-
ated distress. Pre and post-test engagement aligns
with recommendations for community based HCV
testing, as per current UK and World Health
Organisation guidelines [2, 24]. Developing such a hy-
brid model of supported remote testing may increase
acceptability.
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Participants were concerned about the relevance of a
test in a context of uncertain HCV treatment access,
with people who use drugs facing barriers to treatment
access both in the UK and globally [1, 21, 42]. As noted
by participants, remote testing does not address or alle-
viate the broader health service and structural issues
which complicate access to HCV treatment for people
who use drugs [21]. In tandem with any efforts to de-
velop testing technologies and signposting to appropriate
care pathways, is the need for action on the social and
structural constraints to HCV treatment access, including,
for example, uneven treatment availability; geographical
access and transport affordability; criminalisation and in-
carceration; discrimination and stigma within healthcare
settings [43].
An overall implication of our findings is to suggest
that HIV remote testing models that prove acceptable
for some groups [44] may not be easily replicated for
HCV for people who use drugs. A model of remote test-
ing as currently formulated may have relevance for
certain populations who are vulnerable to HCV or
within a hybrid model of testing within community ser-
vices. However, specific considerations of the potential
for confusion around testing and linked awareness of
HCV as well as treatment access barriers [28, 45] require
a tailored approach to HCV. The utility of self-sampling
and self-testing is likely to be context, population and
infection specific and so such strategies for HCV will
need further development and evaluation.
These results should be understood within the scope
of the rapid assessment methodology used. Our analysis
should be interpreted cautiously reflecting the limited
time we had to collect data. More research is needed to
elaborate and refine our findings and explore their trans-
ferability to other settings. In particular, the geographic
focus and limit to London suggests any future study
should be expanded to other urban areas, as well as
rural settings within the UK to understand varying need.
An additional priority would be more in-depth study of
usability, in particular more fully including service users
within design and development of the technologies.
However, given the limited evidence for the potential
use of remote HCV testing these qualitative results give
insight in to the perceptions of potential users of remote
testing and so are an important basis for initial policy
deliberations.
Conclusions
Rapid qualitative assessment in London of remote HCV
testing for people who use drugs shows potential accept-
ability alongside many concerns. Current technologies
may only be suitable for a medically literate population
with access to follow-on care and linked support, which
may not be the majority of people who use drugs. In
order to be ethically employed among broader popula-
tions, including those most at risk of HCV acquisition,
developers of remote testing technologies must work
with people who use drugs and service providers to
ensure the inclusion of accessible information and linkage
to care and consider hybrid models using self sampling or
self testing in existing provider services. While explora-
tory, we envisage that our findings will help inform policy
discussions and health care delivery as well as debate
amongst potential service users in the UK and elsewhere
as this emergent technology is explored.
Abbreviation
HCV: Hepatitis C
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